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Abstract. Burkholderia pseudomallei is a Gram-negative environmental bacterium found in tropical climates that
causes melioidosis. Culture remains the diagnostic gold standard, but isolation of B. pseudomallei from heavily contam-
inated sites, such as fecal specimens, can be difficult. We recently reported that B. pseudomallei is capable of infecting the
gastrointestinal tract of mice and suggested that the same may be true in humans. Thus, there is a strong need for new
culture techniques to allow for efficient detection of B. pseudomallei in fecal and other specimens. We found that the
addition of norfloxacin, ampicillin, and polymyxin B to Ashdown’s medium (NAP-A) resulted in increased specificity
without affecting the growth of 25 B. pseudomallei strains. Furthermore, recovery of B. pseudomallei from human clinical
specimens was not affected by the three additional antibiotics. Therefore, we conclude that NAP-Amedium provides a new
tool for more sensitive isolation of B. pseudomallei from heavily contaminated sites.
INTRODUCTION
Burkholderia pseudomallei is a saprophytic bacterium pre-
sent in soil and surface water that causes melioidosis in humans
and animals.1 Major endemic areas include southeast Asia and
northern Australia, although as diagnostic facilities improve,
the bacterium has been isolated from additional countries in
tropical and subtropical latitudes.1,2 Melioidosis can be an
acutely fatal disease, with many patients succumbing shortly
after clinical presentation, although long latency periods of up
to 62 years have been reported.3,4 Infection is thought to occur
after inoculation, inhalation, or ingestion, although the contri-
bution of each route is not fully understood.1 Symptoms are
highly protean, and proper diagnosis is critical, because timely
administration of appropriate antibiotics is important for clear-
ance of B. pseudomallei.5–7 Culture remains the gold standard
for diagnosis, and although B. pseudomallei can grow on most
common laboratory media, isolation from non-sterile sites
requires the use of selective media.
A number of selective media have been developed for
B. pseudomallei, although the selective medium that has been
shown provide the best combination of sensitivity and speci-
ficity for isolation of B. pseudomallei is Ashdown’s medium
(ASH).8–10 ASH contains crystal violet and gentamicin as
selective components as well as glycerol and neutral red to
allow for differentiation based on colony morphology.8 Mul-
tiple modifications of ASH and other selective media have
been developed using different antibiotics, including colistin
(polymyxin E), polymyxin B, chloramphenicol, vancomycin,
penicillin, ampicillin, streptomycin, amikacin, and increased
gentamicin concentrations to improve specificity.9,11–17
Although some media formulations have included multiple
antibiotics, most have used a single antibiotic to improve
selectivity. Moreover, to our knowledge, fluoroquinolones
have not yet been investigated as an additive to selective
medium for B. pseudomallei.
Intrinsic antibiotic resistance is a hallmark ofB. pseudomallei.
For instance, numerous antibiotics belonging to different
classes are extruded from the cell by resistance nodulating cell
division (RND) efflux pumps. For example, AmrAB-OprA is
responsible for the intrinsic aminoglycoside and macrolide
resistance observed with most B. pseudomallei strains.18,19
In strain KHW, BpeAB-OprA was also shown to efflux
aminoglycosides, but this finding was not corroborated by stud-
ies with strain 1026b, where this pump was shown to confer
low-level chloramphenicol, fluoroquinolone, macrolide, and
tetracycline resistance but not extrude aminoglycosides.20,21
Certain fluoroquinolones have also been shown to be effluxed
(T. Mima and others, unpublished observations), and other
studies have shown that alterations in DNA gyrase can lead to
resistance.22 In addition, the B. pseudomallei genome encodes
seven putative Ambler class A, B, and D b-lactamases.23–26
Of these b-lactamases, only the PenA Class A b-lactamase
has been shown to confer clinically significant b-lactam resis-
tance.24 Finally, the cell envelope structure, notably lipo-
polysaccharide, is known to be responsible for resistance to
cationic peptides, such as polymyxins.27 Although significant
levels of antibiotic resistance are a major challenge in treating
patients with melioidosis, these Burkholderia traits provide
options for development of selective media.
Selective media have improved B. pseudomallei isolation
rates, although B. pseudomallei recovery from certain sites can
still be challenging. For instance, although B. pseudomallei has
been isolated from rectal swabs of melioidosis patients, over-
growth of enteric bacteria was also reported.28 Therefore, we
investigated the ability of the addition of norfloxacin, ampi-
cillin, and polymyxin B to improve the specificity of ASH
for recovery of B. pseudomallei from clinical specimens.
These antibiotics were chosen because of their previous
use in B. pseudomallei-selective media (ampicillin and poly-
myxins),12,16,17,29 intrinsic resistance among B. pseudomallei
isolates (norfloxacin, ampicillin, and polymyxins),30–32 and pre-
vious use against enteric flora (norfloxacin and ampicillin).33
This report describes the optimization of the new medium
norfloxacin, ampicillin, and polymyxin B ASH medium
(NAP-A medium). Specificity and sensitivity studies were
performed using samples from infected mice. In addition,
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a side-by-side comparison of recovery rates using NAP-A
and ASH medium was done using human clinical samples.
MATERIALS ANDMETHODS
Bacterial strains and growth conditions. A detailed descrip-
tion of B. pseudomallei strains used in this study is provided in
Table 1. Briefly, B. pseudomallei strains included 12 clinical
strains (7 blood, 3 pus, and 2 lung isolates), 10 environmental
isolates, and 4 clinical isolates commonly used in laboratory
experiments. All B. pseudomallei strains were originally iso-
lated in Thailand, and provided by Sharon Peacock (Mahidol
University, Mahidol, Thailand and University of Cambridge,
Cambridge, United Kingdom). Routine experiments involving
B. pseudomallei were performed with strain 1026b, a strain
isolated from the blood of a melioidosis patient in Thailand.34
Other B. pseudomallei isolates, B. thailandensis strains, and
additional Burkholderia spp. strains are described in Table 1.
Freezer stocks of all bacterial strains were prepared from
stationary phase Luria–Bertani (LB) broth (BD Biosciences,
San Jose, CA) cultures grown at 37°C with shaking at 250 rpm.
Sterile glycerol (Fisher Scientific, Pittsburgh, PA) was added
to each culture at a 20% (vol/vol) final concentration, and
glycerol stocks were frozen at −80°C. Unless noted, plating
of pure bacterial cultures was performed using bacteria
thawed directly from freezer stocks. In experiments where
overnight cultures were used, cultures were grown in LB broth
at 37°C with shaking at 250 rpm, and stationary phase cultures
were used for plating. All procedures involvingB. pseudomallei
performed at Colorado State University were performed in a
Biosafety Level 3 (BSL3) facility in accordance with approved
BSL3 and Select Agent protocols.
Mice and animal infections. Female BALB/c and C57BL/
6 mice were purchased from Jackson Laboratories (Bar
Harbor, ME). Male and female Institute for Cancer Research
(ICR) mice were purchased from Harlan Laboratories
(Indianapolis, IN). All mice used in experiments were housed
under pathogen-free conditions in microisolator cages, and
mice were 12–20 weeks of age at the time of infection.
Oral (p.o.) and intranasal (i.n.) infection of mice with
B. pseudomallei was performed as described previously.35
Immediately before animal inoculation, bacterial stocks frozen
in LB broth with 20% glycerol were thawed and diluted
in sterile phosphate buffered saline (PBS; Sigma-Aldrich,
St. Louis, MO). Infectious doses were determined by plating
serial dilutions of each inoculum on LB agar (BD Biosciences,
San Jose, CA). Oral inoculations were performed with a stain-
less steel 22-gauge gavage needle, and mice were inoculated
in a total volume of 100 mL. For i.n. inoculation, mice were
anesthetized with intraperitoneal (i.p.) injection of ketamine
(100 mg/kg; Pfizer, New York, NY) and xylazine (10 mg/kg;
Lloyd Laboratories, Shenandoah, IA), and inoculations were
done using in a total volume of 20 mL (10 mL per nostril).
Median lethal dose (LD50) values for acute disease (i.e.,
euthanasia required on or before day 7) in BALB/c mice were
previously determined to be 1.04 + 107 cfu for p.o. infection
and 9 + 102 cfu for i.n. infection with B. pseudomallei strain
1026b.35 All experiments involving animals were approved
by the Institutional Animal Care and Use Committee at
Colorado State University and performed in accordance with
the National Institutes of Health guidelines for the humane
use of laboratory animals.
Antibiotic preparation and storage. Gentamicin was pur-
chased as a pre-made solution in deionized water (10 mg/mL).
Norfloxacin powder was dissolved at a concentration of
100 mg/mL in glacial acetic acid and then diluted to a final
concentration of 10 mg/mL with PBS. Based on previous
studies showing that low pH buffers increase the stability of
ampicillin, ampicillin powder was dissolved in 0.1 M acetate
buffer (pH 6) at a concentration of 50 mg/mL.36,37 Polymyxin
B powder was dissolved in deionized water at a concentration
of 2.5 + 105 units/mL. Vancomycin powder was dissolved in
deionized water at 0.5 mg/mL. Rifampicin powder was dissolved
in dimethyl sulfoxide at 50 mg/mL. Fosfomycin powder was
dissolved in deionized water at 50 mg/mL. All reagents were
purchased from Sigma-Aldrich (St. Louis, MO).
Table 1
Bacterial strains
B. pseudomallei B. thailandensis Burkholderia spp.
Clinical* and laboratory strains Environmental strains
Strain Source Strain Source Strain Source Species Source
2613a Blood E0008 Thailand E264 Thailand B. oklahomensis 60
2650a Blood E0031 Thailand E421 Thailand B. gladioli pv. cocovenenans 61
2668a Blood E0037 Thailand E426 Thailand B. dolosa 62
2674a Blood E0237 Thailand B. ubonensis 63
2692a Blood E0342 Thailand B. vietnamiensis A. Hoffmaster†
2704a Blood E0356 Thailand
2671a Blood E0377 Thailand
2617a Pus E0383 Thailand
2618a Pus E0386 Thailand
2685a Pus E0394 Thailand
2670a Lung
2719a Lung
1026b Blood34
K96243 Human26
1710b Blood58
1106b Pus59
*All Strain isolated from patients in Ubon Ratchatani in northeast Thailand.
†Centers for Disease Control and Prevention.
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Gentamicin solutions were stored at 4°C according to the
manufacturer’s instructions. Stock solutions of norfloxacin,
ampicillin, and polymyxin B were stored at −80°C and used
within 6 months as determined by stability experiments
performed in the current investigation (see below).
Selective media preparation. Modified trypticase soy agar.
Modified trypticase soy agar (MTSA) was prepared as
described previously.8 Briefly, 4% glycerol (Fisher Scientific,
Pittsburgh, PA), 5 mg/mL crystal violet (EMD Science,
Gibbstown, NJ), and 50 mg/mL neutral red (Sigma-Aldrich, St.
Louis, MO) were added to trypticase soy agar (BBL 211043;
BD Biosciences, San Jose, CA).
ASH. ASH was also prepared as described previously.8
Briefly, MTSA was prepared as described above, autoclaved,
and cooled to 55°C, and gentamicin was added at a final
concentration of 4 mg/mL.
NAPA-A. NAP-A was prepared by using ASH medium
as the basal medium and incorporating three additional anti-
biotics. MTSA was prepared as described above, autoclaved,
and cooled to 55°C, and gentamicin at 4 mg/mL, norfloxacin
at 4 mg/mL, ampicillin at 10 mg/mL, and polymyxin B at
300 units/mL were added.
Additional selective media.Norfloxacin, ampicillin, and poly-
myxin B MTSA (NAP-MTSA) was prepared the same as
the NAP-A medium described above, although gentamicin
was not added. LB agar with gentamicin, norfloxacin, ampi-
cillin, and polymyxin B was also prepared by autoclaving
LB agar, cooling the media to 55°C, and adding gentamicin
at 4 mg/mL, norfloxacin at 4 mg/mL, ampicillin at 10 mg/mL,
and polymyxin B at 300 units/mL.
Fecal pellet collection and processing. Fecal pellets were
collected from mice and processed as described previously.35
Briefly, mice were transferred into small plastic containers,
and fecal pellets were then collected from these containers.
Fecal pellets were resuspended in PBS at a concentration
of 0.1 g feces/mL PBS and homogenized using a Stomacher
80 Biomaster (Seward, Port Saint Lucie, FL). Serial dilutions
of fecal homogenates were prepared in sterile PBS and plated
on agar plates. The lower limit of bacterial detection in feces
was 10–60 cfu/g feces.
Optimization of norfloxacin, ampicillin, and polymyxin B
concentrations. Based on previous reports showing that ASH
medium provides the best combination of specificity and
sensitivity, the ability of additional antibiotics to improve the
specificity of ASH was investigated.9,10 Optimized concentra-
tions of norfloxacin, ampicillin, and polymyxin B were deter-
mined using 10 different enteric bacteria colony types that
were routinely cultured from murine gastrointestinal (GI)
tissues plated on ASH (isolates were not identified on a genus
or species level). These 10 isolates were subcultured onto
ASH medium supplemented with different concentrations of
each antibiotic. Several different concentrations of all three
antibiotics were evaluated for their ability to suppress endog-
enous flora. To determine if enteric bacteria capable of grow-
ing in the presence of gentamicin would be susceptible to a
different antibiotic in the same class, streptomycin was inves-
tigated at 10 mg/mL.38
Determination of organ bacterial burden. Bacterial burden
in organ homogenates was quantitated as described previ-
ously.35 Mice were euthanized, and organs were placed in
4 mL sterile PBS. Before homogenization, the stomach and
cecum were cut into ~1- to 2-cm2 sections, and small intestine
and colon tissues were cut open longitudinally and then cut
into 2- to 3-cm lengths. Organs were homogenized using a
Stomacher 80 Biomaster, and serial 10-fold dilutions of organ
homogenates were prepared in sterile PBS. Organ homoge-
nates and serial dilutions were plated on LB, ASH, or NAP-A
agar plates. Unless noted, agar plates were incubated at 37°C,
and colonies were counted at 48 hours. The limit of detection
in organ homogenates was 20 cfu/organ.
Clinical evaluation. To assess the use of NAP-A medium to
isolate B. pseudomallei from human clinical samples, the
medium was compared with ASH in a small-scale evaluation
in a diagnostic laboratory in an endemic area (Microbiology
Laboratory, Mahosot Hospital, Vientiane, Lao People’s
Democratic Republic). Clinical samples that were being
cultured routinely for B. pseudomallei on ASH and in a selec-
tive broth based on ASH containing colistimethate (SBCT;
50 mg/L)17 that was subcultured onto ASH after 48 hours of
incubation were also cultured on NAP-A plates in parallel.
The formulations of media were similar to those formulations
described above, except that the local recipe for ASH cur-
rently in use was followed. This recipe comprised 10 g
Tryptone soya broth (Oxoid, Basingstoke, United Kingdom),
15 g Agar No. 1 (Oxoid, Basingstoke, United Kingdom),
40 mL glycerol (VWR, East Grinstead, United Kingdom), 5 mL
0.1% crystal violet (Merck, Beeston, United Kingdom), and
5 mL 1% neutral red (Rankem, Faridabad, India) per 1 L,
to whichgentamicin for injection (Bidiphar,QuyNon,Vietnam)
was added to give a final concentration of 5 mg/mL. For
NAP-A medium, norfloxacin, ampicillin, and polymyxin
(Sigma-Aldrich, St. Louis, MO) were added to achieve the
same final concentrations as listed above. Cultures on ASH
were read as usual by the clinical laboratory staff, whereas
NAP-A cultures were read by another staff member who was
blind to the results of ASH cultures. The study was carried out
in two phases. During the first phase, the presence or absence
of B. pseudomallei was recorded qualitatively (i.e., present or
absent). During the second phase, the growth of both B.
pseudomallei and other competing flora on both media was
recorded semiquantitatively according to the method by Nye
and others.39
Stability of antibiotic stock solutions. The Kirby–Bauer
disk diffusion method was chosen to investigate the stability
of antibiotic stock solutions used in NAP-A medium.36,40 The
disk diffusion assay was performed according to the Clinical
and Laboratory Standards Institute guidelines.41 Antibiotic
stocks were prepared as described above, aliquoted, and
stored at either 4°C or −80°C. At various time points after
preparation, an aliquot from each antibiotic was tested for the
ability to kill Escherichia coli strain DH5a.42 E. coli was grown
overnight on Mueller Hinton (MH; BD Biosciences, San Jose,
CA) agar plates, and bacterial colonies were resuspended
in sterile PBS at a density equivalent to a 0.5 MacFarland
standard. The bacterial suspension was then streaked on an
MHagar plate using a sterile swab to create a lawn of bacteria;
6-mm disks (Whatman, Piscataway, NJ) were loaded with the
desired amount of antibiotic (gentamicin [10 mg], norfloxacin
[10 mg], ampicillin [10 mg], and polymyxin B [300 units]) in a
total volume of 25 mL, and disks were allowed to air dry asep-
tically.43 Antibiotic loaded disks were added to the MH agar
plate containing the E. coli lawn, plates were incubated at
37°C, and zones of inhibition were measured after 16–18 hours
of growth. At each time point, zone diameters were compared
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with zones determined from the original antibiotic stocks
before storage at 4°C or −80°C.
Statistical analysis. Statistical analyses were performed using
Prism 5.0 software (Graph Pad, San Diego, CA). Differences in
percentages of positive samples were compared using a two-
tailed Fisher exact test. Analyses comparing two groups were
done using a two-tailed Student t test, and analyses comparing
more than two groups were performed using a one-way analy-
sis if variance (ANOVA) followed by a Tukey multiple means
comparison test. In experiments comparing two variables,
data were analyzed by a two-way ANOVA followed by a
Bonferroni post-test. Differences were considered statistically
significant for P < 0.05.
RESULTS
While developing a murine model of chronic enteric
melioidosis, we observed that enteric bacteria often overgrew
B. pseudomallei when cultured on ASH.35 The effects of
norfloxacin, ampicillin, and polymyxin B on the growth of
enteric bacteria subcultured from ASH are reported in Table 2.
Norfloxacin selected against 9 of 10, 8 of 10, and 6 of 10 enteric
colonies at concentrations of 10, 5, and 1 mg/mL, respectively
(Table 2). We found that 10 mg/mL ampicillin prevented
growth of all 10 enteric bacteria isolates. However, increasing
the concentration of polymyxin B up to 600 units/mL did not
significantly inhibit enteric isolate growth compared with
ASH (P = 0.06). Only 3 of 10 enteric bacteria were inhibited
by streptomycin, similar to the result with gentamicin.
In summary, these studies showed that 10 or 5 mg/mL
norfloxacin or 10 mg/mL ampicillin significantly reduced the
growth of enteric bacteria. Increasing polymyxin B provided
only minor improvements in selectivity against enteric isolates.
Therefore, studies were performed to investigate the ability of
B. pseudomallei to grow in the presence of antibiotics capable
of inhibiting enteric isolate growth.
B. pseudomallei strain 1026b was serially diluted in PBS and
plated on ASH containing each individual antibiotic. We found
that neither 10 mg/mL ampicillin nor 300 U/mL polymyxin B
affected B. pseudomallei growth. Norfloxacin was tested at 1, 5,
and 10 mg/mL, and it was further titrated over a 2–10 mg/mL
range in 2-mg/mL increments (Table 2) (data not shown).
From these studies, 4 mg/mL was consistently identified as
the concentration that did not alter B. pseudomallei growth
(data not shown). We also evaluated several other antibiotics
for use in selective medium, including fosfomycin, rifampicin,
and vancomycin. However, we found that none of these anti-
biotics offered any particular advantage over the norfloxacin,
ampicillin, and polymixin B combination. Therefore, 10 mg/mL
ampicillin, 4 mg/mL norfloxacin, and 300 units/mL polymyxin B
were chosen for additional study.
To assess the ability of each individual antibiotic to select
against enteric bacteria when added to MTSA, inhibition of
bacterial growth from mouse fecal pellets was used as a screen-
ing method. Fecal pellets were collected from BALB/c,
C57BL/6, and ICR mice and processed as described in
Materials and Methods. Each dissolved fecal pellet sample
was plated on LB, MTSA, and MTSA medium supplemented
with a single antibiotic (Figure 1). MTSA medium alone sig-
nificantly reduced the growth of enteric bacteria compared
with growth on LB (P < 0.001). The addition of each individ-
ual antibiotic to MTSA medium also produced a significant
reduction in enteric bacterial titers compared with MTSA
medium alone (P < 0.001). Comparisons between the different
antibiotics showed that norfloxacin was significantly more
effective than gentamicin (P < 0.05). In addition, compared
with polymyxin B, both norfloxacin (P < 0.01) and ampicillin
(P < 0.05) provided significant reductions in enteric bacterial
growth, although no differences were observed between poly-
myxin B and gentamicin. To summarize, all four antibiotics
reduced the growth of enteric bacteria when added to MTSA,
although ampicillin and norfloxacin seemed to be the most
effective against fecal bacteria. However, none of the antibiotics
Table 2
Titration of additional antibiotics used in NAP-A medium
Medium
Enteric bacteria
B. pseudomallei†Positive P value*
ASH 9/10 NA 8.85 ± 0.06
ASH + 10 mg/mL Nor 1/10 P = 0.001 8.62 ± 0.01
ASH + 5 mg/mL Nor 2/10 P = 0.006 8.88 ± 0.03
ASH + 1 mg/mL Nor 4/10 P = 0.06 8.69 ± 0.04
ASH + 10 mg/mL Amp 0/10 P = 0.0001 8.94 ± 0.08
ASH + 5 mg/mL Amp 4/10 P = 0.06 ND
ASH + 600 U/mL PxB 4/10 P = 0.06 ND
ASH + 500 U/mL PxB 7/10 P = 0.58 ND
ASH + 300 U/mL PxB 8/10 P = 1.0 8.80 ± 0.05
ASH + 10 mg/mL Str 7/10 P = 0.58 ND
Amp = ampicillin; NA = not applicable; ND = not determined; Nor = norfloxacin; PxB =
polymyxin B; Str = streptomycin.
*Statistical differences compared with ASH were determined by a two-tailed Fisher exact
test.
†B. pseudomallei 1026b titers reported as log10 cfu per 1 mL ± SEM.
Figure 1. Effect of individual antibiotics on growth of fecal bac-
teria. Fecal pellets were homogenized in PBS, and serial dilutions
were plated on various agar media. MTSA was supplemented with
gentamicin (4 mg/mL), norfloxacin (4 mg/mL), ampicillin (10 mg/mL),
or polymyxin B (300 U/mL). Fecal pellets were collected from cages of
five mice. Data from BALB/c (N = 15 cages), C57BL/6 (N = 14 cages),
and ICR (N = 12 cages) mice were pooled (N = 41 cages). Samples
were processed as described in Materials and Methods and plated on
each medium. Data are presented as individual log10 cfu per 1 g feces,
with bars representing the mean titer for each group. Statistical dif-
ferences between antibiotics were determined by a one-way ANOVA
followed by a Tukey multiple means test (*P < 0.05; ***P < 0.001).
Data were pooled from seven individual experiments.
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were sufficient to consistently inhibit growth of fecal bacteria
when used alone. Therefore, we concluded that including all
four antibiotics would likely be the most effective formulation
for inhibiting the growth of contaminating flora.
NAP-A medium is more effective at inhibiting enteric
bacterial growth. To access the effectiveness of the new four-
antibiotic NAP-A medium, growth of enteric bacteria in both
GI tissues and fecal pellets was assessed (Figure 2). We found
that use of NAP-A medium resulted in a significant reduction
in enteric bacterial growth from BALB/c, C57BL/6, and ICR
mice compared with ASH medium. For example, enteric bac-
teria from GI tissues of BALB/c mice grew on ASH medium,
whereas enteric bacterial growth was not observed on the
four-antibiotic NAP-A medium (Figure 2). The addition of
these four antibiotics to LB media also prevented enteric
bacterial growth from fecal pellets of BALB/c and C57BL/
6 mice (data not shown). Therefore, the use of four-antibiotic
NAP-A medium significantly reduced the growth of enteric
bacteria from multiple strains of mice, which was assessed by
both qualitative and quantitative assays.
NAP-A medium improves B. pseudomallei isolation from
samples with low bacterial burdens. To determine whether
B. pseudomallei could be isolated from infected GI tissues
using NAP-A medium, tissues obtained from BALB/c mice
infected p.o. or i.n. individually with each of four different
B. pseudomallei strains (strain 1026b, 2671a, 2685a, or 2719a)
were subjected to bacterial culture; 125 GI tissues (stomach,
small intestine (SI), cecum, or colon) were plated in parallel
on both ASH and NAP-A media. No significant differences in
B. pseudomallei titers were observed between samples plated
on ASH versus NAP-A medium (P = 0.35; data not shown).
These results showed that the three additional antibiotics
in NAP-A medium did not affect the ability to isolate
B. pseudomallei from tissues.
A major effect of NAP-A medium was observed when cul-
tures of undiluted organ homogenates (Figure 2B) were com-
pared with cultures on ASH. Therefore, we next assessed the
effect of NAP-A medium on B. pseudomallei detection in tis-
sues with very low levels of infection (titer £ 1,000 cfu/organ).
Of 125 GI samples plated on both NAP-A and ASH, 34 low-
titer samples were identified. In the low-titer samples, a sig-
nificant increase (P = 0.03) in B. pseudomallei titers was
observed on NAP-A medium (Figure 3). This result is likely
caused by the ability of NAP-A medium to prevent the
growth of enteric bacteria, which was often observed to
overgrow B. pseudomallei. Indeed, qualitative examples
were also observed in GI tissues from mice infected with
B. pseudomallei (Figure 3).
The four antibiotics in NAP-A medium did not have an
effect on the growth of B. pseudomallei strain 1026b (Table 2)
(data not shown). However, it was also important to assess
the wider ability of NAP-A medium to be used as a general
culture medium for multiple B. pseudomallei strains. There-
fore, 25 additional B. pseudomallei strains (12 clinical,
Figure 2. Increased selectivity of NAP-A medium compared with ASH. (A) Stomach, small intestine (SI), cecum, colon, and feces tissues
from BALB/c (N = 10), C57BL/6 (N = 11), and ICR (N = 11) mice were homogenized, and serial dilutions were plated on LB, ASH, or NAP-A
medium agar plates. Data are graphed as log10 cfu per organ ± SEM for stomach, SI, cecum, and colon and log10 cfu per 1 g ± SEM for feces.
Differences in bacterial titers between different media in all organs were determined by a two-way ANOVA followed by a Bonferroni post-test
(***P < 0.001). For each mouse strain, data were pooled from two individual experiments. (B) BALB/c mice were infected orally with 4.7 + 105
cfu B. pseudomallei strain 1026b and euthanized 3 days after infection. SI tissue was processed for determination of bacterial burden as described
in Materials and Methods. Growth after culture of the same tissue sample on ASH or NAP-A media is presented. Agar plates were incubated
at 37 °C for 5 days. Quadrants where undiluted (neat) homogenate, and serial dilutions were plated and labeled accordingly.
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10 environmental, and 3 laboratory strains) (Table 1) were
assessed for their ability to grow on NAP-A medium. Over-
night cultures of each strain were prepared in LB broth, and
stationary phase cultures were diluted in sterile PBS and
plated on each agar medium. We found nearly equivalent
growth of all 25 strains on all three media (LB, ASH, or
NAP-A; P = 0.99) (Figure 3). The growth of additional
Burkholderia spp. was also investigated by streaking each
strain onto agar media. Growth was equivalent on both
media, with B. thailandensis, B. oklahomensis, B. dolosa, and
B. ubonensis capable of growth on both ASH and NAP-A,
whereas neither B. gladioli pathovar cocovenenans nor B.
vietnamiensis was able to grow on either medium (data not
shown). In summary, the addition of four antibiotics to the
NAP-A medium did not reduce recovery of multiple different
B. pseudomallei strains from infected tissues. In addition,
NAP-A medium improved isolation of B. pseudomallei from
sparsely colonized tissues without suppressing growth of a
panel of clinical isolates of B. pseudomallei.
Comparison of culture of specimens from suspected human
melioidosis patients on ASH and NAP-A medium. Lastly, we
compared the effectiveness of NAP-A with conventional
ASH medium for recovery of B. pseudomallei from clinical
specimens from humans with suspected B. pseudomallei infec-
tion (melioidosis). A total of 359 consecutive clinical speci-
mens (119 pus/pus swab specimens, 172 throat swabs, 2 mouth
swabs, 2 sputum specimens, and 64 fluid specimens [31 ascitic,
19 pleural, 5 joint, 2 pericardial, 6 Pouch of Douglas, and
1 gastric aspirate]) obtained from patients in Laos was plated
in parallel on ASH medium and NAP-A medium; 16 positive
samples were obtained (7 pus/pus swab, 7 throat swabs, 1 ascitic
fluid, and 1 pleural fluid), and all 16 samples grew on both
ASH and NAP-A medium either on direct plating or through
Figure 3. Increased sensitivity of NAP-A compared with ASH medium. (A) NAP-A medium improves isolation of B. pseudomallei from
tissues with low-level B. pseudomallei colonization (titers £ 1,000 cfu/organ). Data from GI organs plated on ASH and NAP-A media are graphed
as individual log10 cfu per organ values, with bars representing mean values (N = 34). Data were pooled from seven independent experiments.
Statistical differences were determined by a two-tailed Student t test (*P < 0.05). (B) Overnight cultures of 25 B. pseudomallei isolates (12 clinical,
10 environmental, and 3 laboratory strains) were grown in LB broth. Serial dilutions were plated on LB, ASH, or NAP-A medium agar plates.
Data are presented as individual log10 cfu per 1 mL titers, with bars representing the mean titer. Bacterial titers were compared by a one-way
ANOVA. Data are representative of two independent experiments. (C) BALB/c mice were infected orally with 9.1 + 104 cfu B. pseudomallei
strain 2685a, and mice were euthanized 3 days after infection. Colon tissue was processed for determination of bacterial burden as described in
Materials and Methods, and growth after culture of the same tissue sample on ASH or NAP-A media is presented. Agar plates were incubated
at 37 °C for 5 days. Enteric bacteria on ASH medium can be seen as a lawn of mucoid purple colonies. B. pseudomallei can be seen on both ASH
and NAP-A media as red ruffled colonies.
Table 3
Isolation from clinical samples
Total samples ASH NAP-A P value*
B. pseudomallei 359† 16 16‡ 1.0
Commensal flora 150§ 6 0 0.014
*Growth rates on ASH and NAP-A were compared by a two-tailed Fisher exact test.
†Samples were composed of 119 pus/pus swab, 172 throat swab, 64 fluids, 2 mouth swabs,
and 2 sputum samples.
‡One sample was not tested by direct plating but positive when plated after broth culture.
§Samples were composed of 69 throat swab, 48 pus/pus swab, 29 fluids, 2 mouth swabs, and
2 sputum samples.
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enrichment (Table 3). One of the samples that was positive by
direct plating on ASH was not tested by direct plating onto
NAP-A agar in error, but it was positive when broth enrich-
ment cultures were plated on NAP-A medium. In contrast,
there was one sample that was positive by direct plating on
NAP-A but negative on direct plating on ASH, although
B. pseudomallei was isolated after SBCT enrichment on both
media. In general, the NAP-A and ASH plates were read as
positive on the same day of incubation, with the exception of
one each that was read as positive on ASH and NAP-A
24 hours earlier than the other medium. During the second
phase, there were no differences seen between the semiquan-
titative growth of B. pseudomallei colonies from each sample
on the two media (data not shown). These results showed,
therefore, that B. pseudomallei was recovered from patient
specimens equivalently when grown on either ASH or NAP-A
media (P = 1.0).
In the second phase, the ability of NAP-A medium to sup-
press growth of commensal bacteria in human clinical speci-
mens was assessed by semiquantitatively comparing growth of
contaminating bacteria on NAP-A and ASH plates using a
previously described technique.39 Growth of contaminating
flora was investigated in a total of 150 samples (48 pus/pus swab
specimens, 69 throat swabs, 29 fluid specimens, 2 mouth swabs,
and 2 sputum specimens). Contaminating flora growth was not
observed on NAP-Amedium, whereas six samples (four throat
swabs and two pus samples) grew contaminating flora on ASH
medium (two samples on direct culture and all six samples on
SBCT subculture). One specimen had 1–10 colonies, one spec-
imen had > 50 colonies on the direct culture, two specimens
had 10–50 colonies, and four specimens had > 50 colonies on
SBCT subculture. Statistical comparison of the overall fre-
quency of contaminating growth on the two media (Fisher
exact test) revealed a significant reduction in the isolation of
contaminating flora on NAP-A medium compared with ASH
(Table 3) (P = 0.014).
Stability of NAP-A medium. The stability of NAP-A
medium constituent antibiotic solutions was investigated
using the disk diffusion method. These studies showed that
gentamicin, norfloxacin, and ampicillin stock solutions were
stable for 6 months when stored at −80°C, whereas polymyxin B
was stable for 3 months (Figure 4). At 4°C, gentamicin and
norfloxacin remained stable for at least 6 months, whereas
polymyxin B was stable for 3 months. A small but significant
reduction in polymyxin B stability was observed after 3 months
of storage at 4°C or −80°C, although a high degree of stability
was still observed at 6 months. In contrast, ampicillin was only
stable for 2 weeks at 4°C (Figure 4).
The stability of NAP-A plates was investigated by using fecal
bacteria to screen the stability of NAP-A medium compared
with ASH medium after storage at 4°C. After 6 months of
storage at 4°C, enteric bacteria from BALB/c mice was unable
to grow on NAP-A medium (limit of detection = 10 cfu/g),
whereas an average titer of 2.5 log10 cfu/g was isolated
when the same samples were plated on 6-month ASH medium
(Figure 4). However, the stability of NAP-A medium declined
by 9 months of storage at 4°C (Figure 4). However, the
9-month NAP-A enteric bacterial titer was still signifi-
cantly less than the enteric bacterial titer on ASH medium
(P < 0.001). In summary, NAP-A medium remained stable
for at least 6 months when stored at 4°C, and stock solu-
tions of antibiotics used to prepare NAP-A medium could
also be stored for at least 6 months at −80°C.
DISCUSSION
In this report, we describe the development and clinical
evaluation of a modified ASH medium (NAP-A) designed
to suppress growth of commensal and contaminating bacteria
in clinical specimens, while still allowing the growth of
B. pseudomallei, even when present in very low numbers. We
found that addition of norfloxacin, ampicillin, and polymyxin B
to conventional ASH medium resulted in increased specificity
Figure 4. Stability of antibiotic stock solutions and NAP-A
medium agar plates. (A) Antibiotic stock solutions were prepared as
described in Materials and Methods. Stock solutions were aliquoted
and stored at either 4 °C or −80 °C. At various time points after
preparation, aliquots were thawed and assayed by the disc diffusion
assay as described in Materials and Methods. Data at each time point
represent data pooled from two independent experiments with three
technical replicates per experiment (N = 6). Data are graphed as the
mean ± SEM zone of inhibition diameter in millimeters. Statistical
differences compared with time zero samples were determined by
a one-way ANOVA followed by a Tukey multiple means test.
(B) Stability of NAP-A medium agar plates stored at 4 °C. Agar
plates were prepared as described in Materials and Methods and
stored at 4 °C. To test the stability of NAP-A medium, fecal bacteria
from BALB/c mice was plated on ASH and NAP-A media at various
time points after storage at 4 °C. Data are graphed as mean ± SEM
log10 cfu per 1 g titers. Statistical differences in fecal titers between
ASH and NAP-A media at each time point were determined by a
two-way ANOVA followed by a Bonferroni post-test. Data were
pooled from two independent experiments, with six samples per
experiment (N = 12; *P < 0.05; **P < 0.01; ***P < 0.001).
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and sensitivity for isolation of B. pseudomallei from GI tissues
of mice. Moreover, NAP-A was comparable with ASH in
recovery of B. pseudomallei from human clinical specimens,
while still effectively suppressing growth of contaminating
bacterial flora. In addition, NAP-A medium did not
suppress the growth of 25 different clinical isolates of
B. pseudomallei. These results suggest, therefore, that NAP-A
medium may be a suitable alternative to ASH medium for
isolation of B. pseudomallei from clinical specimens with high
levels of contamination with endogenous flora, such as gastro-
intestinal specimens.
Although the oral route of infection with B. pseudomallei
in humans has received relatively little attention, there is
growing epidemiological and clinical evidence that oral infec-
tion may be a primary route of B. pseudomallei infection. For
example, culture-positive drinking water and breast milk have
been associated with melioidosis cases, including two separate
outbreaks in Australia and a case of infant melioidosis.44–47
In addition, ulcers have been reported in the stomach,
small intestine, and colon of melioidosis patients, and
B. pseudomallei has been isolated from gastric fluids, intesti-
nal contents, and rectal swabs of melioidosis patients.28,48–53
Moreover, two mouse models of melioidosis have recently
shown that oral infection results in persistent colonization of
the stomach together with fecal shedding and dissemination to
extraintestinal organs.35,54 Our studies in the murine model of
chronic GI infection also indicated that murine enteric bacteria
often outcompeted B. pseudomallei when grown on ASH.
Thus, we reasoned that overgrowth of enteric bacteria on
ASH would also likely complicate investigation of enteric
B. pseudomallei infection in humans. Until truly effective selec-
tive media for culture of B. pseudomallei from GI and fecal
samples are developed, the true prevalence of GI infection
with B. pseudomallei in humans cannot be determined. Thus,
the new NAP-A mediummay be particularly useful as a means
to begin to assess GI chronic infection with B. pseudomallei.
Although the current study used ASH as the basal medium,
other selective media have been developed for specific isola-
tion ofB. pseudomallei. For example, B. pseudomallei selective
agar (BPSA) has been reported to improve isolation of mucoid
colonies of B. pseudomallei, whereas growth of these mucoid
colonies has been reported to be inhibited on ASH.55 In one
clinical study, however, BPSA medium was found to be equiv-
alent to ASH in its ability to grow B. pseudomallei but also
found to be less selective.10 Additional studies may be
warranted to determine whether the addition of norfloxacin,
ampicillin, and polymyxin B would improve the selectivity of
BPSA medium.
NAP-Amediummayalso improve isolationofB.pseudomallei
from environmental specimens, such as soil or water, by
suppressing growth of the environmental microbiota.
Although ASH and a basal salt solution supplemented with
threonine have been used successfully for the isolation of
B. pseudomallei from soil and water, contaminating bacteria
often complicate environmental studies.56,57 Larger volumes
of soil could potentially be processed, allowing for more readily
performed quantitative analyses and a reduced need for initial
broth culture. Indeed, studies in Laos are currently underway
to determine whether NAP-Amedium could improve isolation
of B. pseudomallei from soil samples.
In summary, culturing heavily contaminated specimens on
NAP-A medium resulted in more effective recovery of isola-
tion of B. pseudomallei from fecal specimens of mice, whereas
recovery of B. pseudomallei from human clinical specimens
was equivalent between ASH and NAP-A medium. We also
determined that NAP-A medium and antibiotic stock
solutions could be stored for extended periods without loss of
activity. Although only a small-scale study comparing clinical
B. pseudomallei isolation with ASH or NAP-A was performed,
the success of these studies warrant additional investigation
of NAP-A medium for recovery of B. pseudomallei from
wound and fecal specimens of melioidosis patients as well as
environmental specimens.
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